- Trials with a EudraCT protocol (149)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
149 result(s) found for: Heart catheterization.
Displaying page 1 of 8.
EudraCT Number: 2015-004485-28 | Sponsor Protocol Number: 38RC15.214 | Start Date*: 2016-01-18 | |||||||||||
Sponsor Name:Centre Hospitalier Universitaire de Grenoble | |||||||||||||
Full Title: | |||||||||||||
Medical condition: Patients should be operated for cardiac surgery with cardiac bypass and in sinus rhythm, and for which the fact of the existence of impaired left ventricular function or the heaviness of the surgic... | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002258-56 | Sponsor Protocol Number: SD-DXP | Start Date*: 2018-08-27 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: The use of xenon and dexmedetomidine for the prevention of postoperative emergence delirium after anaesthesia for pediatric cardiac catheterization: A randomized, controlled, observer-blinded pilot... | ||
Medical condition: xenon-dexmedetomidine Anesthesia in children undergoing cardiac catheterization | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000021-57 | Sponsor Protocol Number: 01000 | Start Date*: 2006-03-10 |
Sponsor Name:Rigshospitalet | ||
Full Title: Bosentan and Sildenfil for patients with Eisenmenger syndrome | ||
Medical condition: Eisenmengers syndrome is condition with severe pulmonary arterial hypertension due to a shunting of blood from the left side of the heart to the right side of the heart. When the pressure in the pu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004828-11 | Sponsor Protocol Number: RECHMPL18_0038_prom_7574 | Start Date*: 2022-01-10 |
Sponsor Name:University Hospital of Montpellier | ||
Full Title: Phosphodiesterase-type 5 inhibitors in adult and adolescent patients with univentricular heart disease: a multi-center, randomized, double blind phase III study | ||
Medical condition: adult and adolescent patients with univentricular heart diseases and pulmonary arterial pressure | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000625-30 | Sponsor Protocol Number: INOT22 | Start Date*: 2004-07-21 |
Sponsor Name:INO Therapeutics | ||
Full Title: Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation Plus Oxygen in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing | ||
Medical condition: : Nitric Oxide for inhalation at 800ppm, plus 100% O2, to be used to assess pulmonary vaso reactivity during Pulmonary Vasodilator Testing | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006748-76 | Sponsor Protocol Number: A1481244 | Start Date*: 2008-04-23 | |||||||||||
Sponsor Name:Pfizer Ltd. Ramsgate Road, Sandwich, Kent, UK | |||||||||||||
Full Title: A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEA... | |||||||||||||
Medical condition: Pulmonary arterial hypertension (PAH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DK (Prematurely Ended) BE (Completed) IT (Prematurely Ended) GR (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001818-42 | Sponsor Protocol Number: C41750/3100 | Start Date*: 2016-04-14 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure D... | |||||||||||||
Medical condition: Chronic Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002510-23 | Sponsor Protocol Number: SR062014 | Start Date*: 2014-09-17 |
Sponsor Name:University hospitals of Leuven | ||
Full Title: as an adjuvant to sevoflurane anaesthesia in children undergoing interventional or diagnostic cardiac catheterization: a randomized controlled clinical trial | ||
Medical condition: Xenon anesthesia in children undergoing cardiac catheterization | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006337-19 | Sponsor Protocol Number: R5381-HF-2159 | Start Date*: 2022-06-08 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN5381, an NPR1 Agonis... | |||||||||||||
Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004815-29 | Sponsor Protocol Number: ULA03 | Start Date*: 2021-08-04 | |||||||||||
Sponsor Name:Cardiorentis AG | |||||||||||||
Full Title: Open-label, dose escalation study of ularitide for the investigation of hemodynamic effects in patients with pulmonary arterial hypertension (UPAH) | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017168-17 | Sponsor Protocol Number: GS-US-270-0101 | Start Date*: 2010-05-31 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction | |||||||||||||
Medical condition: Heart failure with Preserved Ejection Fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006072-32 | Sponsor Protocol Number: 2019/ABM/01/00078 | Start Date*: 2022-10-05 | |||||||||||
Sponsor Name:University Hospital in Poznań | |||||||||||||
Full Title: Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction | |||||||||||||
Medical condition: Heart Failure with reduced ejection fraction. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003338-15 | Sponsor Protocol Number: RBHP2014ELJEZI | Start Date*: 2014-12-01 | |||||||||||
Sponsor Name:CHU de Clermont-Ferrand | |||||||||||||
Full Title: Role of Nitric Oxide (NO) in pre-oxygenation before anesthetic induction in patients with Pulmonary Hypertension (PH) in cardiac surgery. Feasibility study. | |||||||||||||
Medical condition: - Cardiac surgery open heart - Pulmonary Hypertension with PAPs> 40 mmHg secondary to left heart disease or COPD (class 2 or 3), diagnosed by preoperative right heart catheterization or transthora... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022820-61 | Sponsor Protocol Number: Tad-10 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: PHASE CONTRAST MAGNETIC RESONANCE (MR) IMAGING IN MONITORING THE EFFECTS OF TADALAFIL IN PATIENTS WITH OUT-OF-PROPORTION PULMONARY HYPERTENSION AND LEFT VENTRICULAR DYSFUNCTION | |||||||||||||
Medical condition: Pulmonary Hypertension ``out-of-proportion`` associated to moderate left ventricular dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003495-53 | Sponsor Protocol Number: NL59009.018.16 | Start Date*: 2016-11-29 |
Sponsor Name:Academic Medical Center - Cardiology | ||
Full Title: Prostacyclin receptor agonist Selexipag in patients with pulmonary arterial hypertension and congenital heart disease | ||
Medical condition: Pulmonary arterial hypertension related to congenital heart disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000833-35 | Sponsor Protocol Number: CRLX030A2201 | Start Date*: 2011-10-24 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, phase II, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure. | |||||||||||||
Medical condition: Acute Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012450-20 | Sponsor Protocol Number: AC-051-206 | Start Date*: 2009-10-15 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: Multicenter, open-label, non-comparative, proof-of-concept, phase 2a study to evaluate the effect of a single infusion of tezosentan on pulmonary vascular resistance in patients with stable, chroni... | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024210-65 | Sponsor Protocol Number: STATIPLAT | Start Date*: 2011-06-01 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Evaluation of antiplatelet drug response after load of statins in patients undergoing coronary angioplasty with stenting. | |||||||||||||
Medical condition: ischemic heart disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005220-16 | Sponsor Protocol Number: SöS exendin 1 | Start Date*: 2007-06-11 | ||||||||||||||||
Sponsor Name:Karolinska institutet | ||||||||||||||||||
Full Title: Cardiovascular fysiological effects of Exenatide on heart failure | ||||||||||||||||||
Medical condition: We are studying a diabetic ( type II) population with decompensated heart failure. Our aim is to see wether Cardiac index and "wedge pressure", measured by heart catheterization, can improve with ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005713-40 | Sponsor Protocol Number: 69HCL20_1135 | Start Date*: 2021-08-02 |
Sponsor Name:Hospices Civils de Lyon | ||
Full Title: Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure patients on heart transplant waiting list: a multicenter, double-blind, randomized clinical trial. | ||
Medical condition: for advanced Heart Failure patients on heart transplant waiting list | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
